Late-Breaking Data Presentation Reveals How UroLift PUL’s Post-Operative Events Compare With Other Minimally Invasive Procedures and Traditional Surgery for the Treatment of BPHWAYNE, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) today announced that new real-world healthcare claims data reveal that the risk of return procedures is lowest after treatment with the UroLift® System among the analyzed benign prostatic hyperplasia (BPH) treatment options. The data also show
Teleflex's (TFX) new real-world data outcomes together with product launches demonstrate the importance of UroLift System for most BPH patients.
New real-world data findings along with new product evolutions demonstrate why the UroLift® System is the right solution for most BPH patients WAYNE, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that two new UroLift System products, the UroLift Advanced Tissue Control (ATC) System and the UroLift 2 System, will be launched at the American Urological Association (AUA) 2021 Annual Meeting taking place virtually September 10–13. New emerging data from th